Scholarlink

<p>The inter-disciplinary relationship between the gut microbiota, mitochondrial function, and inflammation activation represents a frontier in understanding Cardiovascular complications. This comprehensive review provides a framework of the signalling networks that link these three biological systems and their collective impact on cardiovascular disease. The gut microbiota is a diverse ecological community comprising bacterial phyla, including <i>Firmicutes</i>,<i> Bacteroidetes</i>,<i> Proteobacteria</i>,<i> and Actinobacteria</i>, which contribute to the functions of distal organs by producing bioactive metabolites. We systematically examined how microbial dysbiosis participates in inflammasome and mitochondrial-derived cardiovascular pathophysiology. This review also provides insight into various molecular pathways (TLR, PI3K/AKT, JAK/STAT, MAPK, TRPV, CREB, TXNIP, YAP, MyD88 and NLRP3) and therapeutic interventions targeting this axis, including gut microbiota modulation agents, mitochondrial-targeted antioxidants, and inflammasome inhibitors, offering mechanistic insights into their cardioprotective effects. Using current evidence and data from PubMed, Google Scholar, Web of Science, and ResearchGate, we provide a mechanistic understanding of the gut microbiota–mitochondria–inflammasome axis. This triad represents a critical target in cardiovascular health and warrants new diagnostic and therapeutic strategies.</p> Graphical Abstract <p><i>Gut-Heart Axis in CVD</i>: This graphical abstract demonstrates the connection between the gut microbiota, the inflammatory pathway, and cardiovascular diseases. Gut dysbiosis triggers the production of metabolites like short-chain fatty acids (SCFAs) and TMAO that influence inflammatory pathways. The central regulators include mitochondrial dysfunction, which leads to ROS production and inflammatory pathway activation and ultimately contributes to the pathogenesis of CVDs.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Decoding the gut microbiota-mitochondrial-inflammasome axis in cardiovascular disease

  • 期刊论文

  • 发表日期：

    2025年12月1日

查看全文
  • Rupali Chauhan,
  • Khemender Lidoo,
  • Uma Jyoti,
  • Thakur Gurjeet Singh,
  • Sushma Devi

摘要

The inter-disciplinary relationship between the gut microbiota, mitochondrial function, and inflammation activation represents a frontier in understanding Cardiovascular complications. This comprehensive review provides a framework of the signalling networks that link these three biological systems and their collective impact on cardiovascular disease. The gut microbiota is a diverse ecological community comprising bacterial phyla, including Firmicutes, Bacteroidetes, Proteobacteria, and Actinobacteria, which contribute to the functions of distal organs by producing bioactive metabolites. We systematically examined how microbial dysbiosis participates in inflammasome and mitochondrial-derived cardiovascular pathophysiology. This review also provides insight into various molecular pathways (TLR, PI3K/AKT, JAK/STAT, MAPK, TRPV, CREB, TXNIP, YAP, MyD88 and NLRP3) and therapeutic interventions targeting this axis, including gut microbiota modulation agents, mitochondrial-targeted antioxidants, and inflammasome inhibitors, offering mechanistic insights into their cardioprotective effects. Using current evidence and data from PubMed, Google Scholar, Web of Science, and ResearchGate, we provide a mechanistic understanding of the gut microbiota–mitochondria–inflammasome axis. This triad represents a critical target in cardiovascular health and warrants new diagnostic and therapeutic strategies.

Graphical Abstract

Gut-Heart Axis in CVD: This graphical abstract demonstrates the connection between the gut microbiota, the inflammatory pathway, and cardiovascular diseases. Gut dysbiosis triggers the production of metabolites like short-chain fatty acids (SCFAs) and TMAO that influence inflammatory pathways. The central regulators include mitochondrial dysfunction, which leads to ROS production and inflammatory pathway activation and ultimately contributes to the pathogenesis of CVDs.